Pinned Tweet
We published one of the first randomized trials of ambient AI scribes, the fastest-growing generative AI application in healthcare.
238 docs. 72K encounters. 2 tools tested over 2 months. Modest time savings. Reduced burnout. Docs reported better patient engagement.
No major safety signals, but occasional inaccuracies mean vigilance remains key. Longer, multi-center RCTs needed.
ai.nejm.org/doi/full/10.1056…
Excited to share APEX-ADRD, our NIA-funded AI and Technology Collaboratory at UCLA. We fund US teams, startups included, to rigorously test AI for older adults and people with dementia.
LOIs due 11/16. Webinar 11/9, 1:30 PT: uclahs.zoom.us/meeting/regis… RFA: aitcc.ai/rfa/aitc-ara-27-001
1
2
385
Very few AI tools for older adults have been tested in rigorous trials. We want to shrink the path from promising tool to real-world evidence from years to months. Up to $200K ($300K for a trial). Questions: [email protected]
1
33
John Mafi retweeted
My friend the brilliant @kevin_volpp dropped dead
He survived (read abt it: tinyurl.com/ypcpdzpz)
But every year 300-400,000 in the US don't
This week: our @nature article (+A.Schubert J.Ross @m_sendhil M.Lingman) applies AI to this medical mystery
nature.com/articles/s41586-0…
New letter in @JAMANetworkOpen! A clinically-oriented one examining the setting where meds affecting cognition (e.g., antipsychotics) are prescribed from. We find they are disproportionately prescribed from acute or post-acute settings (i.e., emergency room, hospital, SNF). 1/3
John Mafi retweeted
Between 2013 and 2021, older adults with cognitive impairment had higher rates of potentially inappropriate CNS-active prescriptions, most lacking clinical indications.
ja.ma/4qjARAl
John Mafi retweeted
The true cost of the reconciliation bill will be measured in lives—over 50,000 per year.
It’s a predictable result when you cut off insurance to people who are old, poor and sick.
@eric_t_roberts and I discuss in @MSNBC @NBCNews @HarvardHPM @PennLDI
msnbc.com/opinion/msnbc-opin…
John Mafi retweeted
Just out today on Health Affairs' Podcast! Our discussion about our findings of ED underuse by socioeconomically disadvantaged patients:
healthaffairs.org/do/10.1377…
@CathSark17 @jnmafi @DOM_UCLA @UCLA_GIMHSR
John Mafi retweeted
We estimate $272 million in spending for COVID-associated hydroxychloroquine and ivermectin during the PHE. @Health_Affairs
healthaffairs.org/doi/full/1…
John Mafi retweeted
AHEAD OF PRINT | The first two years of the COVID-19 pandemic saw an exponential increase in using repurposed medications to treat infections. Michelle S. Rockwell of @virginia_tech and coauthors explore demographic trends driving the surge in prescriptions and spending on hydroxychloroquine and ivermectin for COVID-19 treatment. Read the full article here: healthaffairs.org/doi/10.137…
John Mafi retweeted
What NIH purports to do here is illegal. In annual appropriations bills for the past several years, Congress has specifically banned NIH from changing indirect costs:
congress.gov/118/plaws/publ4…
Last year, $9B of the $35B that the National Institutes of Health (NIH) granted for research was used for administrative overhead, what is known as “indirect costs.” Today, NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%, above what many major foundations allow and much lower than the 60%+ that some institutions charge the government today. This change will save more than $4B a year effective immediately.
John Mafi retweeted
1/ ‼️ NEW in @JAMAInternalMed.
In our latest, @michelleskeller and I introduce a new research framework for older adults: “Deprescribing Equity.”
A brief 🧵 on why this framework is needed and our recommendations for how we can achieve this goal.
jamanetwork.com/journals/jam…
John Mafi retweeted
1/ NEW 📝 in @JAMANetworkOpen.
In our latest from the REACH-AF Study, we asked: Does the racial & ethnic diversity of your VA medical center impact prescribing of stroke-reducing 💊 for #AFib.
Short answer: YES!
A 🧵 on what we found.
#Pharmacoequity
jamanetwork.com/journals/jam…
Very pleased to host the #SGIM24 Special Symposium on “Medical Misinformation in the Era of Artificial Intelligence” with @UrmimalaSarkar @walidgellad @wee_christina @ProfHayward @SocietyGIM
At the request of my friend, the amazing @drfolamay, I'd like to discuss "Nuances in the Colorectal Cancer Guidelines" for #ColorectalCancerAwarenessMonth. Let's dive into some primary care focused Q&As that shed light on screening and prevention 👇#CRCawareness @UCLAGIHep @esrailian @ArpanPatelMD @JenKolbMD
That's a wrap! Thanks to Trisha James for her support. See these resources for more information: uclahealth.org/medical-servi…
uspreventiveservicestaskforc…























